{"id":"rpn301","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RPN301 activates glucagon-like peptide-1 (GLP-1) receptors, which enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, improving patient compliance while maintaining sustained metabolic benefits.","oneSentence":"RPN301 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:32:58.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT05337228","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2022-08-09","conditions":"Parenteral Nutrition","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RPN301","genericName":"RPN301","companyName":"HK inno.N Corporation","companyId":"hk-inno-n-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RPN301 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}